Proton pump inhibitor use may not prevent high‐grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apt.12693PMID 24617286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus.

  2013cited by this paper
• British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus

  2013cited by this paper
• Incidence of Adenocarcinoma among Patients with Barrett's Esophagus

  2012cited by this paper
• Bile Exposure Inhibits Expression of Squamous Differentiation Genes in Human Esophageal Epithelial Cells

  2012cited by this paper
• Acid suppression increases rates of Barrett's esophagus and esophageal injury in the presence of duodenal reflux.

  2012cited by this paper
• Proximal and distal esophageal sensitivity is decreased in patients with Barrett's esophagus.

  2011cited by this paper
• Effect of Proton-Pump Inhibitor Therapy on Serum Chromogranin A Level

  2011cited by this paper
• Correlation between serum gastrin and cellular proliferation in Barrett’s esophagus

  2011cited by this paper
• Systematic review: the role of bile acids in the pathogenesis of gastro‐oesophageal reflux disease and related neoplasia

  2011cited by this paper
• American Gastroenterological Association medical position statement on the management of Barrett's esophagus.

  2011cited by this paper
• American Gastroenterological Association technical review on the management of Barrett's esophagus.

  2011cited by this paper
• Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

  2011cited by this paper
• Incidence of adenocarcinoma among patients with Barrett's esophagus.

  2011cited by this paper
• Bile acids are multifunctional modulators of the Barrett's carcinogenesis.

  2010cited by this paper
• Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank

  2010cited by this paper
• Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis

  2010cited by this paper
• Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis.

  2010cited by this paper
• Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus

  2010cited by this paper
• Dyspeptic Symptoms and Endoscopic Findings in the Community: The Loiano–Monghidoro Study

  2010cited by this paper
• What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis.

  2010cited by this paper
• Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo

  2009cited by this paper
• Medication usage and the risk of neoplasia in patients with Barrett's esophagus.

  2009influential reference
• Medical treatment of Barrett's esophagus: can it prevent cancer?

  2009influential reference
• Prevalence of Complicated Gastroesophageal Reflux Disease and Barrett’s Esophagus Among Racial Groups in a Multi-Center Consortium

  2009cited by this paper
• Glycine-extended gastrin stimulates proliferation via JAK2- and Akt-dependent NF-kappaB activation in Barrett's oesophageal adenocarcinoma cells.

  2008cited by this paper
• Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation.

  2008cited by this paper
• Effect of proton pump inhibitors on markers of risk for high‐grade dysplasia and oesophageal cancer in Barrett’s oesophagus

  2007cited by this paper
• Gastrooesophageal reflux disease.

  2007cited by this paper
• Using prescription claims data for drugs available over‐the‐counter (OTC)

  2007cited by this paper
• Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.

  2007influential reference
• Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK

  2006cited by this paper
• Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence

  2006cited by this paper
• The Danish Civil Registration System. A cohort of eight million persons.

  2006cited by this paper
• Gastro-oesophageal reflux disease.

  2006cited by this paper
• Prevalence of Barrett's esophagus in the general population: an endoscopic study.

  2005cited by this paper
• Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus

  2004cited by this paper
• Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus

  2004cited by this paper
• Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hospitalization for Intracerebral Hemorrhage: A Population-Based Case-Control Study

  2003cited by this paper
• Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus.

  2002cited by this paper
• Barrett’s oesophagus, dysplasia and pharmacologic acid suppression

  2001cited by this paper
• Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.

  1999cited by this paper
• The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett.

  1996cited by this paper
• Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas.

  1975cited by this paper
• Chronic peptic ulcerz of the œophagus and ‘œsophagitis’

  1950cited by this paper
• Chronic peptic ulcer of the oesophagus and 'oesophagitis'.

  1950cited by this paper

• Amprenavir Mitigates Pepsin-Induced Transcriptomic Changes in Normal and Precancerous Esophageal Cells

  2025cites this paper
• Helicobacter pylori in esophageal carcinogenesis: Potential culprit or forceful defender?

  2025cites this paper
• Pepsin, Mucosal Injury, and Pathophysiology of Non-acid Reflux.

  2025cites this paper
• Integrative GEO and Mendelian randomization analysis reveals transcriptomic and lipidomic features of esophageal adenocarcinoma

  2025cites this paper
• Chemoprevention of Barrett’s Esophagus: a Systematic Review and Comprehensive Assessment of Bias

  2025cites this paper
• Global Transcriptomic Analysis of Topical Sodium Alginate Protection against Peptic Damage in an In Vitro Model of Treatment-Resistant Gastroesophageal Reflux Disease

  2024cites this paper
• Advances in laryngopharyngeal reflux: Etiology, diagnosis, and management

  2024cites this paper
• Trends in incidence, treatment modalities and prognosis of esophageal adenocarcinoma in the US population.

  2024cites this paper
• The association between obesity and malignant progression of Barrett's Esophagus: a systematic review and dose-response meta-analysis.

  2024cites this paper
• Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction

  2023cites this paper
• The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes

  2023cites this paper
• Barrett's esophagus as a premalignant condition; medical and surgical therapeutic management

  2023cites this paper
• Trends in Epidemiology of Esophageal Cancer in the US, 1975-2018

  2023cites this paper
• Systematic Review and Meta-Analysis of the Relationship between Proton Pump Inhibitors and Esophageal Adenocarcinoma.

  2023cites this paper
• Amprenavir inhibits pepsin‐mediated laryngeal epithelial disruption and E‐cadherin cleavage in vitro

  2023cites this paper
• Assessment of the Relationship Between Gastric-Acid Suppressants and the Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis

  2023cites this paper
• Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy

  2022cites this paper
• Barrett’s Oesophagus: Today’s Mistake and Tomorrow’s Wisdom in Screening and Prevention

  2022cites this paper
• Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study

  2022cites this paper
• Possible Association between the Use of Proton Pump Inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case–Control Study Using a Korean National Health Screening Cohort

  2022cites this paper
• Barrett’s Esophagus and Intestinal Metaplasia

  2021influential citation
• Prävention gastrointestinaler Tumore

  2021cites this paper
• Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett’s esophagus: a systematic review and meta-analysis

  2021cites this paper
• Chemoprevention in Barrett’s esophagus and esophageal adenocarcinoma

  2021cites this paper
• The research progress on the association between dietary habits and esophageal cancer: a narrative review.

  2021cites this paper
• Risk of esophageal adenocarcinoma in patients with Barrett’s esophagus using proton pump inhibitors: a systematic review with meta-analysis and sequential trial analysis

  2021cites this paper
• Commentary on: Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis

  2021cites this paper
• Antireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia.

  2021cites this paper
• Cancer Prevention in Patients with GERD and Barrett’s Esophagus—Medicine

  2021cites this paper
• Multinational survey on the preferred approach to management of Barrett’s esophagus in the Asia-Pacific region

  2021cites this paper
• Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis

  2021cites this paper
• Multidisciplinary Management of Gastroesophageal Reflux Disease

  2021cites this paper
• Chemoprevention of esophageal adenocarcinoma

  2020cites this paper
• Pepsin and Laryngeal and Hypopharyngeal Carcinomas

  2020cites this paper
• Zinc Gluconate Induces Potentially Cancer Chemopreventive Activity in Barrett’s Esophagus: A Phase 1 Pilot Study

  2020cites this paper
• Multidisciplinary Management: Alternative Perspectives for the Management of Gastroesophageal Reflux Disease (GERD) and Barrett’s Esophagus (BE)

  2020cites this paper
• Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice

  2020cites this paper
• Proton Pump Inhibitor Controversies

  2020cites this paper
• Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus Using Proton Pump Inhibitors: A Systematic Review With Meta-Analysis and Trial Sequential Analysis

  2020cites this paper
• Laryngopharyngeal reflux and the Mediterranean diet

  2020cites this paper
• Gastrointestinal pharmacology: practical tips for the esophagologist

  2020cites this paper
• RNA Sequencing Reveals Cancer‐Associated Changes in Laryngeal Cells Exposed to Non‐Acid Pepsin

  2020cites this paper
• H+/K+ATPase Expression in the Larynx of Laryngopharyngeal Reflux and Laryngeal Cancer Patients

  2020cites this paper
• Laryngopharyngeal and Gastroesophageal Reflux: A Comprehensive Guide to Diagnosis, Treatment, and Diet-Based Approaches

  2020cites this paper
• Proximal reflux: biochemical mediators, markers, therapeutic targets, and clinical correlations

  2020cites this paper
• Update on Barrett’s esophagus diagnosis and treatment

  2020cites this paper
• Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome

  2019cites this paper
• Perspectives on the interlinked nature of systemic sclerosis and reflux disease

  2019cites this paper
• Barrett’s Esophagus: Diagnosis and Management

  2019cites this paper
• Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma

  2019cites this paper
• Gastroesophageal reflux disease with non-esophageal manifestations, the formation of Barrett’s esophagus on the background of a hiatal hernia

  2019cites this paper
• Pathophysiologie des Adenokarzinoms am ösophagogastralen Übergang (AEG)

  2019cites this paper
• The Evolving Landscape of Esophageal Cancer: A Four-Decade Analysis

  2019cites this paper
• Proton pump inhibitors and the risk of severe adverse events – A cardiovascular bombshell?

  2018cites this paper
• Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case‐control study in US male veterans

  2018cites this paper
• Maintenance proton pump inhibition therapy and risk of oesophageal cancer.

  2018cites this paper
• Clinical and oncopreventive outcomes of antireflux surgery

  2018cites this paper
• Precision care for Barrett's esophagus.

  2018cites this paper
• Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?

  2018cites this paper
• Editorial: less acid, less cancer? Is this the question? Authors’ reply

  2018cites this paper
• Progression of GERD at a Pathological Level

  2018cites this paper
• Progression of GERD at the Clinical Level

  2018cites this paper
• Present Diagnosis and Management of Gastroesophageal Reflux Disease: The Good, Bad, and Ugly

  2018cites this paper
• Proton pump inhibitors and the risk of severe adverse events - A cardiovascular bombshell?

  2018cites this paper
• Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?

  2017cites this paper
• Dietary sugar and Barrett’s esophagus

  2017cites this paper
• Influence of Long-Term Use of Proton Pump Inhibitors on Esophageal and Gastrointestinal Precancerous Lesions or Carcinoma

  2017cites this paper
• Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin‐αv trafficking

  2017cites this paper
• An evolutionary perspective on field cancerization

  2017cites this paper
• Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus: A Systematic Review and Meta-Analysis

  2017cites this paper
• Insights Into the Pathophysiology of Esophageal Adenocarcinoma.

  2017cites this paper
• Esophageal Adenocarcinoma : Pathogenesis, Prevention, and Prognosis

  2017cites this paper
• Past, present and future of Barrett's oesophagus.

  2017cites this paper
• Prevention and Prognosis

  2016cites this paper
• Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

  2016cites this paper
• Aspects on endoscopic characterization and clinical management of Barrett's esophagus

  2016cites this paper
• Opportunities for Preventing Esophageal Adenocarcinoma

  2016cites this paper
• Effects of Non-Steroidal Anti-Inflammatory Drugs on the Gastrointestinal and Cardiovascular System

  2016cites this paper
• Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus

  2016cites this paper
• Gastrin and upper GI cancers.

  2016cites this paper
• Oesophageal adenocarcinoma and gastric cancer: should we mind the gap?

  2016cites this paper
• Estudio de prevalencia, incidencia, supervivencia y factores de riesgo asociados al esófago de barrett y adenocarcinoma esofágico. Utilidad de los biomarcadores twist, p504s y cd133 en la valoración de la progresión del esófago de barrett

  2016cites this paper
• NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case–control study

  2015cites this paper
• Local Synthesis of Pepsin in Barrett’s Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma

  2015cites this paper
• Reflections on esophageal columnar metaplasia (Barrett)‐ANNO 2015

  2015cites this paper
• Clinical Practice Guidelines on the Diagnosis and Treatment of Gastroesophageal Reflux Disease (GERD)

  2015cites this paper
• Recent Advances in Oesophageal Adenocarcinoma

  2015cites this paper
• Reconstruction in the gastroesophageal junction- from routine to advanced.

  2015cites this paper
• Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.

  2015cites this paper
• Chemoprevention in Barrett's Esophagus: Current Status.

  2015cites this paper
• [Complicated gastroesophageal reflux disease in the presence of congenital esophageal shortening].

  2015cites this paper
• The Effect of Proton Pump Inhibitors on Barrett's Esophagus.

  2015cites this paper
• Rat Reflux Model of Esophageal Cancer and Its Implication in Human Disease

  2015cites this paper
• Barrett's esophagus: recent insights into pathogenesis and cellular ontogeny.

  2015cites this paper
• Barrett's oesophagus: frequency and prediction of dysplasia and cancer.

  2015cites this paper
• Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.

  2015cites this paper
• Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction

  2015cites this paper
• Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?

  2015cites this paper
• The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma

  2015cites this paper
• Letter: proton pump inhibitors, GERD and oesophageal adenocarcinoma

  2014cites this paper